Pfizer Inc. Stock
€21.90
Your prediction
Pfizer Inc. Stock
Pros and Cons of Pfizer Inc. in the next few years
Pros
Cons
Performance of Pfizer Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Pfizer Inc. | 0.940% | 1.908% | 0.482% | -15.886% | 2.890% | -51.452% | -27.894% |
| Johnson & Johnson | -0.590% | -0.746% | 2.116% | 27.161% | -0.611% | 7.359% | 34.174% |
| Biogen Inc. | 1.030% | 6.258% | 6.574% | 10.821% | 7.641% | -36.992% | -21.870% |
| Elanco Animal Health Inc. | -0.510% | 3.820% | 13.443% | 78.157% | 3.229% | 68.099% | -22.253% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.When diving into the financials of Pfizer Inc. (PFE), a major player within the pharmaceuticals industry, a mixed picture starts to emerge. On the one hand, the company boasts a solid revenue stream and demonstrates a commendable operating margin, creating an impression of profitability. On the other hand, several warning signs appear in the form of declining growth metrics and concerns over income stability. Now, let’s break down the analysis into pros and cons to provide a comprehensive view.
Strong Revenue Performance: Pfizer reported a total revenue of approximately $54.89 billion over the trailing twelve months. This figure suggests that the company has maintained a robust sales figure, driven largely by their pharmaceutical portfolio, including well-known products and newly developed vaccines.
Healthy Operating Margins: The operating margin, standing at around 31.63%, illustrates the company's efficiency in turning sales into profit. This is relatively strong for the pharmaceutical sector, indicating that Pfizer is effectively managing its operating expenses relative to its revenue.
Comments
News
Prediction: 2 Healthcare Stocks That Will Be Worth More Than Pfizer by the End of 2026
Pfizer's (NYSE: PFE) shares have been southbound for the last three years. And unfortunately for the company, it doesn't look like things will improve significantly in 2026. The pharmaceutical
Want Over $2,000 in Dividends Each Year? Invest $12,000 Each Into These 3 Stocks
Dividend stocks can be the ultimate investments to buy and forget about. They'll generate recurring income for your portfolio, even if you've forgotten you own them. What's important, however, is to
Pfizer's Stock Just Dropped 6%. Can the Pharmaceutical Giant Bounce Back in 2026?
A rising tide doesn't lift all boats. For example, a boat with gaping holes in its hull will sink regardless of how high the tide rises. Pfizer (NYSE: PFE) seemed to be the investing equivalent of